✦ LIBER ✦

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

✍ Scribed by Richard G. Langley; Steven R. Feldman; Chenglong Han; Brad Schenkel; Philippe Szapary; Ming-Chun Hsu; Jean-Paul Ortonne; Kenneth B. Gordon; Alexa B. Kimball

Book ID: 116585893
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 415 KB
Volume: 63
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2009.09.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of ustekinumab on health-related

Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB

Ustekinumab improves health-related qual

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

✍ M. Lebwohl; K. Papp; C. Han; B. Schenkel; N. Yeilding; Y. Wang; G.G. Krueger 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

Efficacy and safety of topical WBI-1001

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial

✍ R. Bissonnette; C. Bolduc; C. Maari; S. Nigen; J.M. Webster; L. Tang; M. Lyle 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

Oxymorphone Extended-Release Tablets Rel

Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial

✍ Alan K. Matsumoto; Najib Babul; Harry Ahdieh 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Safety and efficacy (PASI 90 and global

Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Impact of adalimumab treatment on health

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis

✍ D. Revicki; M.K. Willian; J.-H. Saurat; K.A. Papp; J.-P. Ortonne; C. Sexton; A. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB